Clinical Trials /

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552

Description:

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose (RP2D) (Part 3).

Related Conditions:
  • Multiple Myeloma
Recruiting Status:

Not yet recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
  • Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Clinical Trial IDs

  • ORG STUDY ID: CR108920
  • SECONDARY ID: 2017-002400-26
  • SECONDARY ID: TALMMY1001-PT3
  • NCT ID: NCT04634552

Conditions

  • Hematological Malignancies

Interventions

DrugSynonymsArms
TalquetamabJNJ-64407564Part 3: Cohort A (Talquetamab)

Purpose

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose (RP2D) (Part 3).

Detailed Description

      Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions,
      increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a
      humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bispecific antibody designed
      to target G protein-coupled receptor family C group 5-member D (GPRC5D) and the CD3 molecule
      found on T lymphocytes (T cell). This study consists 3 periods: screening phase (up to 28
      days), treatment phase (start of study drug administration and continues until the completion
      of the end of treatment [EOT (30 days (+ 7 days)] visit); and a post-treatment follow-up
      phase (until the end of study unless the participant has died, is lost to follow up or has
      withdrawn consent). Total duration of study is up to 2 years (after the last participant
      receives their first dose). Safety, pharmacokinetics (PK), laboratory tests, and
      questionnaire will be assessed at specified time points during this study. Participants
      safety and study conduct will be monitored throughout the study. The corresponding study
      (NCT03399799) is the Phase 1 part of the study and TALMMY1001- Part 3 is the Phase 2 part of
      the study.
    

Trial Arms

NameTypeDescriptionInterventions
Part 3: Cohort A (Talquetamab)ExperimentalCohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
  • Talquetamab
Part 3: Cohort B (Talquetamab)ExperimentalCohort B will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
  • Talquetamab

Eligibility Criteria

        Inclusion Criteria:

          -  Documented initial diagnosis of multiple myeloma according to international myeloma
             working group (IMWG) diagnostic criteria

          -  Part 3: Measurable disease cohort A and cohort B: multiple myeloma must be measurable
             by central laboratory assessment

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

          -  Women of childbearing potential must have a negative pregnancy test at screening and
             prior to the first dose of study drug using a highly sensitive pregnancy test either
             serum (beta human chorionic gonadotropin [hCG]) or urine

          -  Willing and able to adhere to the prohibitions and restrictions specified in this
             protocol

        Exclusion Criteria:

          -  Part 3 only: Cohort A only: exposed to a CAR-T or T cell redirection therapy at any
             time. Cohort B: T cell redirection therapy within 3 months

          -  Vaccinated with live, attenuated vaccine within 4 weeks or as recommended by the
             product manufacturer prior to the first dose, during treatment, or within 100 days of
             the last dose of talquetamab

          -  Toxicities from previous anticancer therapies should have resolved to baseline levels
             or to Grade 1 or less except for alopecia or peripheral neuropathy

          -  Received a cumulative dose of corticosteroids equivalent to >= 140 milligram (mg) of
             prednisone within the 14-day period before the first dose of study drug (does not
             include pretreatment medication)

          -  Stroke or seizure within 6 months prior to signing the informed consent form (ICF)
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Overall Response Rate (ORR)
Time Frame:Up to 15 months
Safety Issue:
Description:ORR is defined as the proportion of participants who have a partial response (PR) or better according to the international myeloma working group (IMWG) criteria.

Secondary Outcome Measures

Measure:Duration of Response (DOR)
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG criteria.
Measure:Very Good Partial Response (VGPR) or Better Rate
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:VGPR or better rate is defined as the percentage of patients who achieve a VGPR or better according to IMWG response criteria.
Measure:Complete Response (CR) or Better Rate
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:CR or better rate is defined as the percentage of patients who achieve CR or better according to IMWG response criteria.
Measure:Stringent Complete Response (sCR) Rate
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:sCR rate is defined as the percentage of patients who achieve sCR according to IMWG response criteria.
Measure:Time to Response (TTR)
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.
Measure:Progression-Free Survival (PFS)
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:PFS is defined as time from date of first dose of study drug to date of first documented PD, per IMWG criteria, or death due to any cause, whichever occurs first.
Measure:Overall Survival (OS)
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:OS is defined as the time from the date of first dose of study drug to the date of the participant's death.
Measure:Minimal Residual Disease (MRD) Negative Rate
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:MRD negativity rate is measured only for participants who achieve at least a CR but is reported based on (intent to treat) ITT similar to the other response data.
Measure:Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Measure:Number of Participants with Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Measure:Number of Participants with AEs by Severity
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
Measure:Number of Participants with Abnormalities in Clinical Laboratory Values
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:Number of participants with abnormalities in clinical laboratory values (such as hematology, serum chemistry and coagulation) will be reported.
Measure:Serum Concentration of Talquetamab
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:Serum samples will be analyzed to determine concentrations of talquetamab.
Measure:Number of Participants with Talquetamab Antibodies
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:Antibodies to talquetamab will be assessed to evaluate potential immunogenicity.
Measure:Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC QLQ-C30)
Time Frame:Baseline up to 2 years and 10 months
Safety Issue:
Description:The EORTC- QLQ-Core-30 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.
Measure:Change from Baseline in HRQoL as Assessed by EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L)
Time Frame:Baseline up to 2 years and 10 months
Safety Issue:
Description:The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores for the 5 separate questions are categorical and cannot be analyzed as cardinal numbers.
Measure:Change from Baseline in HRQoL as Assessed by Patient Global Impression of Severity (PGIS)
Time Frame:Baseline up to 2 years and 10 months
Safety Issue:
Description:The PGIS is a single item that assesses severity of the participant's health state, on a 5-point verbal rating scale. Score ranges from 1 (None) to 5 (Very Severe).
Measure:Overall Response Rate (ORR) in Participants with High-risk Molecular Features
Time Frame:Up to 2 years and 10 months
Safety Issue:
Description:ORR in participants with high risk is defined as the overall response rate among the high risk molecular subgroups or other high-risk molecular subtypes.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Janssen Research & Development, LLC

Trial Keywords

  • Multiple Myeloma

Last Updated

November 18, 2020